Clinical Trial Update: Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety, tolerability, and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy Indian infants when administered with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunization Vaccination in Infants
• Pneumococcal Infection

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Vaccines | Phase 4 | Status: COMPLETED | Results posted: 2020-09-30